Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Fox

Showing results (161-170 of 179) with videos related to

Pageof 18
Sort By:
The Lancet. Psychiatry|June 9, 2018
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trialRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
International Psychogeriatrics|July 19, 2022
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Martin Knapp, Susan Stirling, et al.
Health Technology Assessment (Winchester, England)|February 7, 2022
A multidomain decision support tool to prevent falls in older people: the FinCH cluster RCTPhilippa A Logan, Jane C Horne, Frances Allen, et al.
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Trials|December 6, 2017
PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trialSimon P Hammond, Jane L Cross, Lee Shepstone, et al.
Neuroepidemiology|February 5, 2020
Dementia Research Fit for the Planet: Reflections on Population Studies of Dementia for Researchers and Policy Makers AlikeCarol E Brayne, Linda E Barnes, Monique M B Breteler, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Age and Ageing|January 25, 2021
The effectiveness and cost-effectiveness of assistive technology and telecare for independent living in dementia: a randomised controlled trialRobert Howard, Rebecca Gathercole, Rosie Bradley, et al.
Annals of Vascular Surgery|January 24, 2025
Higher Rate of Reinterventions after Transfemoral Carotid Artery Stenting in Symptomatic Patients: A Retrospective Stroke Center's Cohort Study Between 2015-2024Camila Esquetini-Vernon, James F Meschia, Josephine Huang, et al.
JCI Insight|October 5, 2016
Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against <i>Toxoplasma gondii</i>Kamal El Bissati, Aziz A Chentoufi, Paulette A Krishack, et al.
Pageof 18

Showing results (161-170 of 179) with videos related to

Sort By:
Pageof 18
The Lancet. Psychiatry|June 9, 2018
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trialRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
International Psychogeriatrics|July 19, 2022
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trialCatherine Henderson, Martin Knapp, Susan Stirling, et al.
Health Technology Assessment (Winchester, England)|February 7, 2022
A multidomain decision support tool to prevent falls in older people: the FinCH cluster RCTPhilippa A Logan, Jane C Horne, Frances Allen, et al.
Health Technology Assessment (Winchester, England)|November 6, 2023
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trialSube Banerjee, Nicolas Farina, Catherine Henderson, et al.
Trials|December 6, 2017
PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trialSimon P Hammond, Jane L Cross, Lee Shepstone, et al.
Neuroepidemiology|February 5, 2020
Dementia Research Fit for the Planet: Reflections on Population Studies of Dementia for Researchers and Policy Makers AlikeCarol E Brayne, Linda E Barnes, Monique M B Breteler, et al.
Health Technology Assessment (Winchester, England)|December 4, 2018
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCTRobert Howard, Elizabeth Cort, Rosie Bradley, et al.
Age and Ageing|January 25, 2021
The effectiveness and cost-effectiveness of assistive technology and telecare for independent living in dementia: a randomised controlled trialRobert Howard, Rebecca Gathercole, Rosie Bradley, et al.
Annals of Vascular Surgery|January 24, 2025
Higher Rate of Reinterventions after Transfemoral Carotid Artery Stenting in Symptomatic Patients: A Retrospective Stroke Center's Cohort Study Between 2015-2024Camila Esquetini-Vernon, James F Meschia, Josephine Huang, et al.
JCI Insight|October 5, 2016
Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against <i>Toxoplasma gondii</i>Kamal El Bissati, Aziz A Chentoufi, Paulette A Krishack, et al.
Pageof 18